Tanabe Mitsubishi Starts Global Phase III Trials With Alzheimer’s Drug
This article was originally published in PharmAsia News
Executive Summary
Tanabe Mitsubishi has begun global Phase III trials for Alzheimer’s disease drug MT-4666 (encenicline) for which they have rights in Japan and other Asian countries.